Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study ( CHAMP ‐ MM )
Cancer Medicine · 2026
DOI: 10.1002/cam4.72332 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Jian Cui und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi, National Natural Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
The therapeutic landscape for newly diagnosed multiple myeloma (NDMM) in China has evolved significantly with wider access to novel agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies. However, real‐world data on treatment patterns and outcomes, particularly among high‐risk subgroups, remain limited. The CHAMP‐MM study aimed to evaluate real‐world frontline and post‐initial relapse treatment patterns and outcomes in NDMM patients, including high‐risk subgroups, defined as those age ≥ 65 (elderly), with renal impairment (RI), and with 1q cytogenetic abnormalities. The study utilized electronic medical record data from five tertiary hematologic centers in China. Adult patients diagnosed with active MM between 2018 and 2022 were included and followed until last visit or end of study (December 31, 2023). A total of 1139 patients were analyzed, including 364 elderly, 148 with RI, and 334 with 1q abnormalities. PI+IMiD‐based regimens were the most common frontline therapy (50.0%) overall, as well as in elderly patients and 1q subgroups, whereas PI‐based regimens were more frequently used in RI patients. Only 25.1% of NDMM patients received autologous stem cell transplant after induction. Following initial relapse, PI+IMiD‐based (32.6%) and CD38‐based (30.9%) regimens predominated. Frontline overall response rates were approximately 80% across all groups, whereas the proportion of patients achieving very good partial response (PR) or better ranged from 60.9% to 75.1% across subgroups. While overall 12‐ and 24‐month progression‐free survival (PFS) rates remained high, outcomes were poorer in high‐risk subgroups. This study reflects real‐world treatment trends in China over 5 years and emphasizes the continued need for tailored treatment approaches in high‐risk populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
- Tianjin Institutes of Health Science, Tianjin, China.
- LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Key Laboratory of Vascular Aging, Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- Sanofi
- National Natural Science Foundation of China
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Tianjin Natural Science Foundation Project
- Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
Zitieren
APA
Cui, J., Qu, X., Li, C., Li, F., Zhong, L., Fu, X., Liu, G., Qiu, L., & An, G. (2026). Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study ( CHAMP ‐ MM ). Cancer Medicine. https://doi.org/10.1002/cam4.72332
Vancouver
Cui J, Qu X, Li C, Li F, Zhong L, Fu X, et al. Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study ( CHAMP ‐ MM ). Cancer Medicine. 2026. doi:10.1002/cam4.72332
BibTeX
@article{Cui2026,
author = {Cui, Jian and Qu, Xiaoyan and Li, Chunrui and Li, Fei and Zhong, Liye and Fu, Xiaohong and Liu, Gang and Qiu, Lugui and An, Gang},
title = {Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study ( CHAMP ‐ MM )},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72332}
}
EUVIMED